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Abstract
Angiotensin-converting enzyme-2 (ACE2) and Mas receptor are the major compo-
nents of the ACE2/Ang 1-7/Mas axis and have been shown to play a protective role 
in hypertension and hypertensive nephropathy individually. However, the effects of 
dual deficiency of ACE2 and Mas (ACE2/Mas) on Ang II-induced hypertensive ne-
phropathy remain unexplored, which was investigated in this study in a mouse model 
of hypertension induced in either ACE2 knockout (KO) or Mas KO mice and in double 
ACE2/Mas KO mice by subcutaneously chronic infusion of Ang II. Compared with 
wild-type (WT) animals, mice lacking either ACE2 or Mas significantly increased blood 
pressure over 7-28 days following a chronic Ang II infusion (P < .001), which was fur-
ther exacerbated in double ACE2/Mas KO mice (P < .001). Furthermore, compared to 
a single ACE2 or Mas KO mice, mice lacking ACE2/Mas developed more severe renal 
injury including higher levels of serum creatinine and a further reduction in creatinine 
clearance, and progressive renal inflammation and fibrosis. Mechanistically, worsen 
hypertensive nephropathy in double ACE2/Mas KO mice was associated with mark-
edly enhanced AT1-ERK1/2-Smad3 and NF-κB signalling, thereby promoting renal 
fibrosis and renal inflammation in the hypertensive kidney. In conclusion, ACE2 and 
Mas play an additive protective role in Ang II-induced hypertension and hyperten-
sive nephropathy. Thus, restoring the ACE2/Ang1-7/Mas axis may represent a novel 
therapy for hypertension and hypertensive nephropathy.
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1  | INTRODUC TION
Hypertensive nephropathy is a major complication of hypertension 
and is the main cause of chronic kidney disease (CKD) character-
ized by progressive renal fibrosis and inflammation.1 Angiotensin 
II (Ang II), the major functional peptide of the renin-angiotensin 
system (RAS), has been long recognized as a key mediator in CKD, 
particularly in hypertension-associated nephropathy.1 It is well ac-
cepted that Ang II can be positively regulated by the classical Ang 
I-converting enzyme (ACE)/Ang II/Ang II type 1 receptor (AT1) axis, 
a critical pathway leading to end-stage renal disease.2,3
Accumulating evidence has shown that the pathogenic actions 
of the ACE/Ang II/AT1 axis can be countered by the angioten-
sin-converting enzyme 2 (ACE2)/Ang 1-7/Mas receptor (Mas) axis. 
As a homolog of ACE, the monocarboxypeptidase ACE2 can op-
pose ACE activity via conversion of Ang II to Ang 1-7, which binds 
to the Mas receptor to exert opposite effects on Ang II.4-6 ACE2 
is highly expressed in the normal kidney, mainly located in the 
proximal tubule,7 and plays an essential role in cardiovascular and 
kidney diseases.8 ACE2 deficiency is associated with exaggerated 
kidney injury in mouse models of diabetes, Ang II-induced hyper-
tension and obstructive nephropathy,9-13 whereas treatment with 
human recombinant ACE2 (hrACE2) can slow the progression of 
diabetic and hypertensive kidney injury.14,15 Ang 1-7 is an endoge-
nous ligand for the G protein-coupled receptor Mas.16 When Mas 
is deleted (Mas–/–) in mice with the FVB/N genetic background, 
they have higher blood pressure than their wild-type (WT) coun-
terpart (Mas+/+).17 However, a difference in the mean arterial pres-
sure was not observed in Mas+/+ and Mas–/– mice with the C57BL/6 
background.18 Nevertheless, the genetic deletion of Mas leads to 
glomerular hyperfiltration and microalbuminuria.19 However, the 
role and underlying mechanisms of the ACE2/Ang1-7/Mas axis in 
hypertensive nephropathy remain largely unclear, prompting us to 
investigate using a chronic Ang II infusion model of hypertension 
in ACE2 knockout (KO), Mas KO and, importantly, in ACE2/Mas 
double KO mice.
2  | MATERIAL S AND METHODS
2.1 | Mouse model of Ang II-induced hypertension 
in mice lacking ACE2, Mas or ACE2/Mas genes
ACE2 KO and Mas KO mice (both C57BL/6 background) were 
generated as described previously.10,18 To investigate the role of 
the ACE2/Ang1-7/Mas axis in hypertension and hypertensive ne-
phropathy, we created the ACE2/Mas double KO mouse by cross-
breeding the ACE2 KO with the Mas KO mice. Double ACE2/Mas 
KO mice were used after being backcrossed for 8 generations. 
Both single- and double-gene KO mice were identified by geno-
typing with primers as described previously.10,18 Hypertensive 
nephropathy was induced in WT, ACE2 KO, Mas KO and ACE2/
Mas double KO mice (male; 8-10 weeks of age; 20-25 g) by sub-
cutaneous infusion of Ang II at a dose of 1.0 mg/kg per day or 
saline as the control for 28 days via osmotic mini-pumps (Model 
2004; ALzet, California).20,21 Blood pressure (BP) was measured by 
the tail-cuff method using the CODA non-invasive blood pressure 
system (Kent Scientific, Torrington, CT) in conscious mice accord-
ing to the manufacturer's instructions. Each mouse was precondi-
tioned to the blood pressure monitoring procedure for at least 5 
cycles before the systolic BP was recorded. The value of systolic 
BP was the average of 10 readings. Mice were euthanized by ex-
sanguination under anesthesia with pentobarbitone (100 mg/kg 
i.p.) at day 28 after Ang II infusion. Kidney tissues were collected, 
and the renal cortex was dissected and used for Western blot 
and real-time polymerase chain reaction (PCR) analyses. The ex-
perimental procedures were approved by the Animal Experimental 
Ethics Committee at The Chinese University of Hong Kong.
2.2 | Proteinuria and renal function analysis
Twenty-four-hour urine was collected at day 28 after Ang II infu-
sion for urinary protein measurement using the Quick StartTM 
Bradford Dye Reagent (Bio-Rad Laboratories, CA, USA). Serum cre-
atinine (Scr) and urinary creatinine were detected by an Enzymatic 
Creatinine LiquiColor Reagent kit (Stanbio Laboratory, Boerne, TX, 
USA) according to the manufacturer's instructions. The creatinine 
clearance was calculated using the following formula: [urine creati-
nine (μmol/L) × 24 h urine volume (ml)]/[24 × 60 (min) × serum cre-
atinine (μmol/L)].
2.3 | Immunohistochemistry
Changes in renal morphology were examined in periodic acid 
Schiff (PAS)-stained paraffin sections (4 μm), and glomerular me-
sangial matrix expansion was scored by counting 30 glomeruli on 
PAS-stained section and expressed as 0-4 point scale (0 = normal; 
1 = mild, <25%; 2 = moderate, 25%-50%; 3 = severe, 50%-75%; 
4 = glomerulosclerosis, >75%). Immunohistochemistry was per-
formed in paraffin sections (3 μm) using the microwave-based 
antigen-retrieval method.20,21 The primary antibodies used in the 
present study were as follows: anti-collagen I (#1310-01, Southern 
Technology, Birmingham, AL, USA), anti-F4/80 (MCA497, Serotec, 
Oxford, UK), anti-phospho-Smad3 (#600-401-919, Rockland 
K E Y W O R D S
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Immunochemicals, Gilbertsville, PA, USA), anti-phospho-p65 
(ab47395, Abcam, Cambridge, MA, USA) and anti-monocyte chem-
oattractant protein-1 (MCP-1) (sc-1304, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA). Positive signals were measured by the 
Image-Pro Plus 6.5 quantitative image analysis system (Media 
Cybernetics, Rockland, MD, USA) as described previously.20,21 
Briefly, the positive immunostaining signal was selected from the 
stained kidney tissue sections, and quantitatively measured and 
expressed as the percentage of the area of the field examined, and 
at least 8 fields of views were quantified for each section. F4/80-
positive, phospho-Smad3-positive and phospho-p65-positive cells 
were enumerated under high-power fields (×40) by means of a 
0.0625-mm2 graticule fitted in the eyepiece of the microscope and 
expressed as cells/mm2, and 10 to 20 fields of views were quanti-
fied for each section.
2.4 | Western blot analysis
Renal cortical tissues were collected for Western blot analysis as 
described previously.20,21 The following antibodies were used: anti-
alpha-smooth muscle actin (α-SMA) (M0851, DAKO); anti-collagen I 
(#1310-01, Southern Technology, Birmingham, AL, USA); anti-phos-
pho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (#4376), anti-phos-
pho-Smad3 (Ser423/Ser425) (#9520), anti-phospho-IκBα (Ser32) 
(#2859), anti-IκBα (#9242), anti-phospho-p65 (Ser536) (#3031) and 
anti-p65 (#6956) (Cell Signaling Technology, Danvers, MA, USA); 
anti-interleukin (IL)-1β (sc-7884), anti-AT1 (sc-1173), anti-Smad 
ubiquitination regulatory factors 2 (Smurf2) (sc-25511) and anti-
Smad7 (sc-7004) (Santa Cruz Biotechnology); anti-Smad3 (#511500, 
Invitrogen - Thermo Fisher Scientific, Carlsbad, CA, USA); anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (MAB374, 
Chemicon, Temecula, CA, USA); and LI-COR IRDye 800-labelled 
secondary antibodies (Rockland Immunochemicals). The signals 
were detected using an Odyssey Infrared Imaging System (Li-COR 
Biosciences, Lincoln, NE, USA) and quantified using the ImageJ pro-
gram (http://imagej.nih.gov/ij/). The ratio of the protein examined 
was normalized against GAPDH and expressed as a mean ± standard 
error of the mean (SEM).
2.5 | Real-time PCR analysis
Total RNA was extracted from kidney tissues using TRIzol®, and 
mRNA levels of collagen I, α-SMA, IL-1β, renin, angiotensinogen, ami-
nopeptidase A (APA) and aminopeptidase N (APN) were detected by 
real-time PCR as described previously. The PCR primer sequences 
were listed in Table 1. The housekeeping genes GAPDH were used 
as internal controls. The ratio of the mRNA examined to GAPDH was 
calculated and is expressed as mean ± SEM.
2.6 | Statistical analysis
Data obtained from this study were expressed as mean ± SEM. 
Statistical analyses were performed using one-way ANOVA using 
Prism 5.0 (GraphPad Software, San Diego, CA, USA).
3  | RESULTS
3.1 | Double deficiency of ACE2/Mas genes 
significantly increases blood pressure and impairs 
renal functions in response to Ang II infusion
Compared with WT animals, mice with single deletion of ACE2 or 
Mas, or double deletion of ACE2/Mas developed normally without 
detectable abnormalities in blood pressure (Figure 1A), bodyweight 
(Figure 1B), or renal function as determined by serum creatinine (Scr, 
Figure 1C) and creatinine clearance (Ccr, Figure 1D). All mice receiv-
ing chronic Ang II infusion developed hypertension (Figure 2A), ele-
vated Scr (Figure 2C) and reduced Ccr (Figure 2D), accompanied by a 
significant increase in proteinuria (Figure 2B). In contrast, mice lack-
ing either ACE2 or Mas developed more severe hypertension and 
renal functional injury, which were further enhanced in mice with 
double deletion of ACE2/Mas (Figure 2A-D). Chronic Ang II infusion 
also caused a moderate glomerular hypercellularity and mesangial 
matrix expansion in the WT mouse kidneys, which were further in-
creased in mice lacking either ACE2 or Mas gene and became more 
severe in those with double deletion of ACE2 and Mas (Figure 2E).
TA B L E  1   Real-time PCR primer sequences





Collagen I GAGCGGAGAGTACTGG ATCG TACTCGAACGGGAATCCA TC
α-SMA GTCCCAGACATCAGGGAGT AA TCGGATACTTCAGCGTCA GGA
IL-1β CTTCAGGCAGGCAGTAT CACTCAT TCTAATGGGAACGTCACAC ACCAG
GAPDH GCATGGCCTTCCGTGTTC GATGTCATCATACTTGGCAG GTTT
Abbreviations: APA, aminopeptidase A; APN, aminopeptidase N.
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3.2 | Double deletion of ACE2/Mas genes promotes 
Ang II-induced renal fibrosis and inflammation
Chronic Ang II infusion resulted in a moderate increase in the expres-
sion of α-SMA and collagen I mRNA and protein in the WT mouse 
kidneys, as demonstrated by real-time PCR, Western blot analysis 
(Figure 3A,B). These fibrotic changes were significantly enhanced 
in Ang II-infused mice that lacked either ACE2 or Mas gene. Mice 
with double deletion of ACE2/Mas developed greater amounts of 
renal fibrosis indicated by increases in α-SMA and collagen I mRNA 
and protein expression when compared with WT and single ACE2 
or Mas gene KO mice (Figure 3A,B). Immunohistochemistry also re-
vealed that ACE2/Mas double deficiency further accelerated the 
accumulation of collagen I in the tubulointerstitium (Figure 3C).
Immunohistochemistry, real-time PCR and Western blot analy-
sis detected that chronic Ang II infusion also induced renal inflam-
mation in the kidneys of WT mice as shown by increasing F4/80+ 
macrophage infiltration (Figure 4A) and up-regulation of MCP-1 and 
IL-1β (Figure 4B-D). These changes were potentiated in either ACE2 
KO or Mas KO mice and to an even greater extent in mice with dou-
ble deficiency of the ACE2 and Mas genes (Figure 4).
3.3 | Double deletion of ACE2/Mas genes promotes 
Ang II-induced renal fibrosis by enhancing AT1-ERK1/2 
MAPK-Smad3 signalling in the hypertensive kidneys
We then examined the possible mechanisms related to renal fibro-
sis in hypertensive mice with either ACE2 or Mas KO or their double 
KO. It has been well documented that Smad3 signalling is critical for 
Ang II-induced renal and cardiac fibrosis via both TGF-β-dependent 
and AT1-ERK1/2-Smad3 crosstalk pathways.20-25 Thus, we investi-
gated whether deficiency of ACE2 and/or Mas exacerbated Ang II-
induced renal fibrosis via the AT1-ERK1/2-Smad3 signalling pathway. 
Western blot analysis demonstrated that a chronic Ang II infusion 
increased the expression of AT1 receptors and up-regulated ERK1/2 
and Smad3 signalling as indicated by increased phospho-ERK1/2 and 
phospho-Smad3, respectively, in the kidneys of WT mice (Figure 5A). 
These changes were significantly increased in mice with single dele-
tion of ACE2 or Mas, and much greater in mice with double deficiency 
of ACE2/Mas. Immunohistochemistry also detected that either ACE2 
or Mas deficiency enhanced Ang II-induced phospho-Smad3 nuclear 
translocation in the hypertensive kidney, which was further increased 
in mice lacking both ACE2 and Mas genes (Figure 5B).
The other components of RAS, including renin, angiotensinogen, 
aminopeptidase A (APA) and aminopeptidase N (APN), were also in-
vestigated in mice with a chronic infusion of Ang II. Real-time PCR re-
vealed that a single or double deletion of ACE2 and Mas had no effect 
on renin, APA and APN mRNA expression, whereas angiotensinogen 
mRNA expression was significantly reduced in Mas or double ACE2/
Mas KO mice but remained unchanged in ACE2 KO mice (Figure 6).
3.4 | Double deletion of ACE2/Mas genes promotes 
Ang II-induced renal inflammation via Smurf2-
mediated loss of smad7 dependent activation of NF-
κB signalling
We have previously demonstrated that Smad7, an inhibitor of TGF-β/
Smad signalling, can also inactivate Ang II-induced NF-κB signalling 
F I G U R E  1   Mice with double deletion 
of angiotensin (Ang)-converting enzyme-2 
(ACE2) and Mas genes develop normally 
with a normal range of blood pressure and 
renal function. A, Systolic blood pressure 
(SBP). B, Bodyweight. C, Serum creatinine 
(Scr). D, Creatinine clearance (Ccr). Data 
represent the mean ± SEM for groups of 
3-5 mice
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through inducing IκBα, an NF-κB inhibitor.26-29 We also find that 
Ang II can induce an E3-ligase, Smurf2, which can bind and degrade 
Smad7, thereby promoting Smad3-dependent renal fibrosis and NF-
κB-mediated renal inflammation.20,24 Similarly, the present study 
detected that deletion of ACE2 or Mas enhanced Ang II-mediated 
up-regulation of renal Smurf2, which was associated with a loss of 
renal Smad7, resulting in activation of NF-κB signalling by increas-
ing phospho-IκBα and phospho-NF-κB/p65 subunit levels and 
phospho-NF-κB/p65 nuclear translocation (Figure 7). These changes 
were notably enhanced in the diseased kidney of dual ACE2/Mas 
KO mice (Figure 7). Thus, double deletion of ACE2/Mas enhanced 
Ang II-induced renal inflammation via the Smurf2-mediated loss of 
Smad7-dependent NF-κB signalling.
4  | DISCUSSION
In this study, we found that mice with a single or double deletion 
of ACE2 and Mas gene developed normally with a normal range of 
blood pressure, bodyweight and renal function. However, under hy-
pertensive conditions, a single deletion of ACE2 or Mas gene sig-
nificantly enhanced Ang II-induced hypertension and hypertensive 
F I G U R E  2   Double deletion of 
angiotensin (Ang)-converting enzyme-2 
(ACE2) and Mas receptor enhances Ang 
II-induced hypertension and hypertensive 
renal injury. A, Systolic blood pressure 
(SBP) at weeks 1, 2, 3, and 4. B, 24-hour 
proteinuria. C, Serum creatinine (Scr). D, 
Creatinine clearance rate (Ccr). E, Renal 
periodic acid Schiff (PAS) staining at 
week 4 after Ang II infusion. Glomerular 
mesangial matrix expansion was scored. 
Data represent the mean ± SEM for 
groups of 6-15 mice. *P < .05, **P < .01, 
***P < .001 vs. WT + saline (WT + SL); 
#P < .05, ##P < .01, ###P < .001 vs. 
WT + Ang II; $ P < .05, $$P < .01, 
$$$P < .001 vs. ACE2 KO + Ang II and Mas 
KO + Ang II. Scale bar, 50 μm. WT + SL 
represents wild-type (WT) mice received 
saline infusion; WT + Ang II represents 
WT mice received Ang II infusion; ACE2 
KO + Ang II represents ACE2 KO mice 
received Ang II infusion; Mas KO + Ang II 
represents Mas KO mice received Ang II 
infusion and A/M KO + Ang II represents 
mice with double deletion of ACE2 and 
Mas received Ang II infusion
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nephropathy, which was consistent with the known protective roles 
of ACE2 or Mas in attenuating the detrimental effects of hyper-
tension and hypertensive kidney disease.9,13,30-32 Indeed, ACE2/
Ang 1-7/Mas is considered as a protective pathway to counter-
regulate the pathogenic action of ACE/Ang II/AT1 axis. The binding 
of Ang 1-7 to Mas receptor can antagonize the effects of Ang II.4 
Furthermore, Mas can hetero-oligomerize with the AT1 to form a 
constitutive complex which is stable in the presence of antagonists 
or agonists of AT1 and Mas. Co-expression of Mas in CHO cells can 
reduce AT1-mediated intracellular calcium mobilization and inositol 
phosphate generation, indicating that Mas itself can inhibit the ac-
tions of Ang II..33
A most significant finding from this study was that compared to 
either ACE2 or Mas KO mice, mice with double deletion of ACE2 and 
Mas genes developed more severe hypertension and hypertensive 
nephropathy including higher levels of blood pressure and serum 
creatinine, a significant fall of creatinine clearance, and progressive 
renal inflammation and fibrosis. These observations suggested that 
ACE2 and Mas may work additively to protect against Ang II-induced 
hypertension and hypertensive kidney disease.
Enhanced AT1-ERK1/2-Smad3 signalling could be a key mecha-
nism by which the dual deletion of ACE2 and Mas further promoted 
renal fibrosis in the hypertensive kidney in response to Ang II. It is 
now well accepted that Smad3 is a key profibrotic transcription fac-
tor and plays an essential role in cardiovascular and renal fibrosis 
under high Ang II conditions.20-25 Indeed, Ang II is able to directly 
and indirectly activate Smad3 to cause cardiovascular and renal 
fibrosis via a TGF-β-dependent and ERK1/2-Smad crosstalk path-
way.20-25 We have previously reported that Ang II can induce a rapid 
activation of Smad2/3 at 15 minutes, which results in a subsequent 
F I G U R E  3   Double deletion of 
ACE2 and Mas receptor enhances Ang 
II-induced renal fibrosis. A, Real-time 
PCR detects α-smooth muscle actin 
(α-SMA) and collagen I (Col. I) mRNAs. 
B, Western blot analysis of α-SMA and 
Col. I. C, Col. I deposition detected by 
immunohistochemistry. Data represent 
the mean ± SEM for groups of 5-12 
mice. *P < .05, **P < .01, ***P < .001 vs. 
WT + SL; #P < .05, ##P < .01, ###P < .001 
vs. WT + Ang II; $P < .05, $$P < .01, 
$$$P < .001 vs. ACE2 KO + Ang II and Mas 
KO + Ang II. Scale bar, 100 μm
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expression of collagen I in tubular epithelial cells lacking the TGF-β 
gene. These profibrotic actions are blocked by the AT1 antagonist 
(losartan) and ERK1/2 inhibitor (PD98059).23 In addition, disruption 
of Smad3 prevents Ang II-induced kidney injury by preserving renal 
function, inhibiting renal fibrosis and inflammation, but has no effect 
on Ang II-induced high blood pressure in vivo.20 In renal mesangial 
cells, Ang1-7 treatment can repress Ang II-induced ERK1/2 phos-
phorylation in a dose-dependent manner.34 These findings reveal 
that Ang II may act via the AT1-ERK1/2-Smad3 pathway to mediate 
renal fibrosis, which can be counter regulated by Ang1-7. In addition, 
Ang II can also activate Smad3 by degrading Smad7, a downstream 
inhibitor of TGF-β/Smad signalling, via the Smurf2-dependent ubiq-
uitin-proteasome degradation mechanism.20,24,27,28 Thus, deletion 
of Smad7 promotes but overexpression of Smad7 inhibits Ang 
II-induced AT1-ERK1/2-Smad3-mediated hypertensive nephrop-
athy.27-29 Consistent with these findings, this study demonstrated 
F I G U R E  4   Double deletion of ACE2 
and Mas receptor enhances Ang II-
induced renal inflammation. A, F4/80+ 
macrophages infiltrating the kidney 
detected by immunohistochemistry. B, 
Monocyte chemoattractant protein-1 
(MCP-1) expression in the kidney detected 
by immunohistochemistry. C, Western 
blot and Real-time PCR (D) analysis 
of Interleukin (IL)-1β expression. Data 
represent the mean ± SEM for groups 
of 6-12 mice. *P < .05, ***P < .001 vs. 
WT + SL; #P < .05, ##P < .01, ###P < .001 
vs. WT + Ang II; $P < .05, $$$P < .001 vs. 
ACE2 KO + Ang II and Mas KO + Ang II. 
Scale bar, 50 μm (A) or 100 μm (B)
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F I G U R E  5   Double deletion of ACE2 
and Mas receptor enhances Ang II-
induced activation of AT1, ERK1/2, and 
Smad3 signalling in the hypertensive 
kidney. A, Western blot analysis of 
Ang II receptor type 1 (AT1), phospho-
ERK1/2 (p-ERK1/2), phospho-Smad3 
(p-Smad3). B, Immunohistochemistry 
of p-Smad3 nuclear translocation. Data 
represent the mean ± SEM for groups 
of 6-12 mice. *P < .05, ***P < .001 vs. 
WT + SL; #P < .05, ##P < .01, ###P < .001 
vs. WT + Ang II; $P < .05, $$P < .01, 
$$$P < .001 vs. ACE2 KO + Ang II and/or 
Mas KO + Ang II. Scale bar, 50 μm
F I G U R E  6   Double deficiency of ACE2 
and Mas genes inhibits angiotensinogen 
but not Renin, Angiotensinogen, 
Aminopeptidase A mRNA expression in 
the hypertensive kidney. Renal mRNA 
expression of Renin, Angiotensinogen, 
Aminopeptidase A (APA) and 
Aminopeptidase N (APN) is detected 
by Real-time PCR. Data represent the 
mean ± SEM for groups of 8 mice. #P < 
.05 vs. WT + Ang II; $P < .05, $$P < .01 vs. 
ACE2 KO + Ang II and/or Mas KO + Ang II
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again that a chronic Ang II infusion led to a moderate activation of 
AT1-ERK1/2-Smad3 signalling and produced a moderate renal fibro-
sis by increasing accumulation of α-SMA and collagen I matrix. A sin-
gle deletion of ACE2 or Mas increased further AT1-ERK1/2-Smad3 
signalling and renal fibrosis, which became more severe in mice 
lacking both ACE2/Mas genes. Thus, enhanced AT1-ERK1/2-Smad3 
signalling may be a mechanism by which loss of the ACE2/Ang 1-7/
Mas axis exacerbated renal fibrosis in ACE2/Mas double KO mice.
It is well established that Ang II acts via AT1 to activate NF-κB 
signalling that mediates renal inflammation. Consistent with this no-
tion, the present study found that a single deletion of ACE2 or Mas 
sustained AT1-NF-κB-driven renal inflammation, which was further 
increased in mice with ACE2/Mas double deletion. Furthermore, 
Ang II can also activate NF-κB by degrading Smad7 as Smad7 is ca-
pable of inducing IκBα, an inhibitor of NF-κBα.20,21,25-29 Consistent 
with these findings, enhanced Ang II-induced NF-κB-dependent 
renal inflammation in ACE2 KO, Mas KO and ACE2/Mas double KO 
mice was also associated with increasing Smurf2-dependent ubiqui-
tin degradation of Smad7.
It should be pointed out that there are several notable limitations 
in this study. First, the present study was performed in global ACE2 or 
Mas gene KO mice, and thus, it is difficult to distinguish the systemic 
versus the local effect of ACE2 and Mas on Ang II-induced hyperten-
sion and hypertensive kidney injury. Second, it has been reported that 
antibodies against AT1 receptor are non-specific,35-37 which may in-
ference the outcome and interpretation of the AT1 results. However, 
as it has been well established that Ang II acts via AT1 to activate NF-
κB-driven inflammation and Smad3-dependent fibrosis, the marked 
differences in AT1-associated TGF-β/Smad3-mediated renal fibrosis 
and NF-κB-dependent renal inflammation in response to Ang II as seen 
in the present study remained meaningful. Third, although chronic 
Ang II infusion did cause a compensatory increase in urinary Ang 1-7 
F I G U R E  7   Double deletion of ACE2 
and Mas receptor enhances Ang II-
induced activation of nuclear factor κB 
(NF-κB) signalling in the hypertensive 
kidney. A, Western blot analysis of 
Smad ubiquitination regulatory factors 2 
(Smurf2), Smad7, phospho-IκBα (p-IκBα), 
and phospho-NF-κB/p65 (p-p65). B, 
Immunohistochemistry of NF-κB/p-p65 
nuclear translocation. Data represent 
the mean ± SEM for groups of 6-12 
mice. *P < .05, ***P < .001 vs. WT + SL; 
#P < .05, ##P < .01, ###P < .001 vs. 
WT + Ang II; $P < .05, $$$P < .001 vs. 
ACE2 KO + Ang II and Mas KO + Ang II. 
Scale bar, 50 μm
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production to counteract the effect of Ang II in WT mice, which was 
reduced in mice lacking ACE2 or ACE2/Mas, but not in Mas KO mice, 
we failed to obtain meaningful levels of Ang 1-7 in serum and intrarenal 
tissues due to its low concentrations. Thus, changes in urinary levels 
of Ang 1-7 remain unexplained and may require further investigation.
In summary, ACE2 and Mas may function additively to protect 
against Ang II-mediated hypertension and hypertensive nephropa-
thy as mice with double deletion of ACE2 and Mas developed more 
severe hypertension and hypertensive nephropathy when compared 
to either ACE2 or Mas KO mice. Enhanced AT1-ERK1/2-Smad3 sig-
nalling may be a key mechanism by which the dual deletion of ACE2 
and Mas further promoted hypertension and hypertensive kidney 
disease. Results from this study reveal that the ACE2/Ang 1-7/Mas 
axis represents opportunities for the future development of thera-
peutics against hypertensive disorders.
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